NCT02421042View on ClinicalTrials.gov

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Hepatic ImpairmentHepatic Function

Interventions

DRUG

Lenvatinib

5- or 10-mg single oral dose of E7080, depending on their hepatic status \[Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)\].

Trial Locations (5)

32809

Orlando

33014

Miami

33169

Miami

37920

Knoxville

55404

Minneapolis

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY

NCT02421042 - A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg) | Biotech Hunter | Biotech Hunter